118 related articles for article (PubMed ID: 29854415)
1. Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric?
Conway DS; Cecilia Vieira M; Thompson NR; Parker KN; Meng X; Fox RJ
Mult Scler J Exp Transl Clin; 2018; 4(2):2055217318777894. PubMed ID: 29854415
[TBL] [Abstract][Full Text] [Related]
2. Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis.
Thach AV; Brown CM; Herrera V; Sasane R; Barner JC; Ford KC; Lawson KA
Int J MS Care; 2018; 20(6):251-259. PubMed ID: 30568562
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
Lenz F; Harms L
Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
[TBL] [Abstract][Full Text] [Related]
5. Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.
McKay KA; Evans C; Fisk JD; Patten SB; Fiest K; Marrie RA; Tremlett H
Neuroepidemiology; 2017; 48(3-4):124-130. PubMed ID: 28683461
[TBL] [Abstract][Full Text] [Related]
6. Reasons for nonadherence and response to treatment in an adherence intervention trial for relapsing-remitting multiple sclerosis patients.
Schoor R; Bruce A; Bruce J; Goggin K; Schanfarber B; Bradley-Ewing A; Thelen J; Glusman M; Lynch SG; Strober L; Catley D
J Clin Psychol; 2019 Mar; 75(3):380-391. PubMed ID: 30485422
[TBL] [Abstract][Full Text] [Related]
7. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
Hua LH; Fan TH; Conway D; Thompson N; Kinzy TG
Mult Scler; 2019 Apr; 25(5):699-708. PubMed ID: 29557704
[TBL] [Abstract][Full Text] [Related]
9. Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.
Li P; Ladage VP; Berger J; Chahin S; Jhaveri M; Geremakis C; Doshi JA
Value Health; 2020 Mar; 23(3):328-334. PubMed ID: 32197728
[TBL] [Abstract][Full Text] [Related]
10. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
[TBL] [Abstract][Full Text] [Related]
11. Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60.
Hua LH; Harris H; Conway D; Thompson NR
Mult Scler Relat Disord; 2019 May; 30():252-256. PubMed ID: 30851638
[TBL] [Abstract][Full Text] [Related]
12. Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients.
Nicholas J; Ko JJ; Park Y; Navaratnam P; Friedman HS; Ernst FR; Herrera V
Mult Scler J Exp Transl Clin; 2017; 3(1):2055217317696114. PubMed ID: 28607751
[TBL] [Abstract][Full Text] [Related]
13. Non-compliance with disease modifying therapies in patients with Multiple Sclerosis: A qualitative analysis.
Stratos K; McGarragle K; Thistle J; Vyas MV; Lee L
Mult Scler Relat Disord; 2020 Jun; 41():102016. PubMed ID: 32135497
[TBL] [Abstract][Full Text] [Related]
14. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
17. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
[TBL] [Abstract][Full Text] [Related]
18. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
Burks J; Marshall TS; Ye X
Clinicoecon Outcomes Res; 2017; 9():251-260. PubMed ID: 28496344
[TBL] [Abstract][Full Text] [Related]
19. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
[TBL] [Abstract][Full Text] [Related]
20. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
